Abstract
Aims
To estimate the number of people who have ever injected drugs (defined here as PWID) living in Scotland in 2009 who have been infected with the hepatitis C virus (HCV) and to quantify and characterize the population remaining undiagnosed.
Methods
Information from routine surveillance (n¿=¿22¿616) and survey data (n¿=¿2511) was combined using a multiparameter evidence synthesis approach to estimate the size of the PWID population, HCV antibody prevalence and the proportion of HCV antibody prevalent cases who have been diagnosed, in subgroups defined by recency of injecting (in the last year or not), age (15–34 and 35–64¿years), gender and region of residence (Greater Glasgow and Clyde and the rest of Scotland).
Results
HCV antibody-prevalence among PWID in Scotland during 2009 was estimated to be 57% [95% CI=52-61%], corresponding to 46¿657 [95% credible interval (CI)¿=¿33¿812–66¿803] prevalent cases. Of these, 27¿434 (95% CI¿=¿14¿636–47¿564) were undiagnosed, representing 59% [95% CI=43-71%] of prevalent cases. Among the undiagnosed, 83% (95% CI¿=¿75–89%) were PWID who had not injected in the last year and 71% (95% CI¿=¿58–85%) were aged 35–64 years.
Conclusions
The number of undiagnosed hepatitis C virus-infected cases in Scotland appears to be particularly high among those who have injected drugs more than 1¿year ago and are more than 35¿years old.
To estimate the number of people who have ever injected drugs (defined here as PWID) living in Scotland in 2009 who have been infected with the hepatitis C virus (HCV) and to quantify and characterize the population remaining undiagnosed.
Methods
Information from routine surveillance (n¿=¿22¿616) and survey data (n¿=¿2511) was combined using a multiparameter evidence synthesis approach to estimate the size of the PWID population, HCV antibody prevalence and the proportion of HCV antibody prevalent cases who have been diagnosed, in subgroups defined by recency of injecting (in the last year or not), age (15–34 and 35–64¿years), gender and region of residence (Greater Glasgow and Clyde and the rest of Scotland).
Results
HCV antibody-prevalence among PWID in Scotland during 2009 was estimated to be 57% [95% CI=52-61%], corresponding to 46¿657 [95% credible interval (CI)¿=¿33¿812–66¿803] prevalent cases. Of these, 27¿434 (95% CI¿=¿14¿636–47¿564) were undiagnosed, representing 59% [95% CI=43-71%] of prevalent cases. Among the undiagnosed, 83% (95% CI¿=¿75–89%) were PWID who had not injected in the last year and 71% (95% CI¿=¿58–85%) were aged 35–64 years.
Conclusions
The number of undiagnosed hepatitis C virus-infected cases in Scotland appears to be particularly high among those who have injected drugs more than 1¿year ago and are more than 35¿years old.
| Original language | English |
|---|---|
| Pages (from-to) | 1287-300 |
| Number of pages | 14 |
| Journal | Addiction |
| Volume | 110 |
| Issue number | 8 |
| Early online date | 8 Jun 2015 |
| DOIs | |
| Publication status | Published - Aug 2015 |
Fingerprint
Keywords
- hepatitis C
- evidence synthesis
- people who inject drugs
- prevalence
Cite this
Prevost, T. C., Presanis, A. M., Taylor, A., Goldberg, D. J., Hutchinson, S. J., & De Angelis, D. (2015). Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland. Addiction, 110(8), 1287-300. https://doi.org/10.1111/add.12948